In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic.
about
Effects of daptomycin and vancomycin on tobramycin nephrotoxicity in ratsDevelopment and validation of a UPLC-UV method for the determination of daptomycin in rabbit plasma.In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains.Comparative In vitro activities of daptomycin and vancomycin against resistant gram-positive pathogensPharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection.In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centersBactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations.Dermabacter hominis: a usually daptomycin-resistant gram-positive organism infrequently isolated from human clinical samples.Natural products to drugs: daptomycin and related lipopeptide antibiotics.Platforms for antibiotic discovery.In vitro activities of arylomycin natural-product antibiotics against Staphylococcus epidermidis and other coagulase-negative staphylococciBaseline study to determine in vitro activities of daptomycin against gram-positive pathogens isolated in the United States in 2000-2001In vivo pharmacodynamic activity of daptomycinIdentification of daptomycin-binding proteins in the membrane of Enterococcus hiraeDifferential increased survival of staphylococci and limited ultrastructural changes in the core of infected fibrin clots after daptomycin administration.Assessment of effects of protein binding on daptomycin and vancomycin killing of Staphylococcus aureus by using an in vitro pharmacodynamic modelDaptomycin compared with teicoplanin and vancomycin for therapy of experimental Staphylococcus aureus endocarditis.Comparative efficacy of daptomycin, vancomycin, and cloxacillin for the treatment of Staphylococcus aureus endocarditis in rats and role of test conditions in this determinationIn vitro activities of daptomycin (LY146032) and paldimycin (U-70,138F) against anaerobic gram-positive bacteriaDaptomycin (LY146032) treatment of experimental enterococcal endocarditisAntibacterial activity of the new glycopeptide antibiotic SKF104662.Comparative evaluation of daptomycin (LY146032) and vancomycin in the treatment of experimental methicillin-resistant Staphylococcus aureus osteomyelitis in rabbits.Ex vivo study of serum bactericidal titers and killing rates of daptomycin (LY146032) combined or not combined with amikacin compared with those of vancomycinAntimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations.Bactericidal activity of deptomycin (LY146032) compared with those of ciprofloxacin, vancomycin, and ampicillin against enterococci as determined by kill-kinetic studiesActivity of LY146032 in vitro and in experimental enterococcal pyelonephritis.Activity of LY146032 compared with that of methicillin, cefazolin, cefamandole, cefuroxime, ciprofloxacin, and vancomycin against staphylococci as determined by kill-kinetic studies.Activity of LY146032 against Enterococci with and without high-level aminoglycoside resistance, including two penicillinase-producing strainsMethicillin-resistant staphylococci: detection methods and treatment of infections.In vitro activities of a new lipopeptide, HMR 1043, against susceptible and resistant gram-positive isolatesAntibiotic efficacy is linked to bacterial cellular respiration.Modulation of the cellular accumulation and intracellular activity of daptomycin towards phagocytized Staphylococcus aureus by the P-glycoprotein (MDR1) efflux transporter in human THP-1 macrophages and madin-darby canine kidney cells.Peptidolipins B-F, antibacterial lipopeptides from an ascidian-derived Nocardia sp.Host defense antimicrobial peptides as antibiotics: design and application strategies.Susceptibility of enterococci and epidemiology of enterococcal infection in the 1980sTranscriptional profiling reveals that daptomycin induces the Staphylococcus aureus cell wall stress stimulon and genes responsive to membrane depolarization.Biochemical characterization of cardiolipin synthase mutations associated with daptomycin resistance in enterococci.Methicillin-resistant staphylococci.Resistance to vancomycin and teicoplanin: an emerging clinical problem.Use of multivariate analysis to compare antimicrobial agents on the basis of in vitro activity data
P2860
Q28330353-D328A60B-8D79-4A9C-B2DD-C31F81BD852FQ33507941-DD4EB01A-C12A-4D3A-893F-A9F52A2E1FE2Q33979251-D75D91EA-B620-40B6-85A9-8480C812555DQ33981048-1CC4BCD0-10CD-4D77-A96C-4E44E512CB02Q33981666-DA6D6815-1590-49D4-980D-A48F9AF81D40Q33982424-71A11C1B-5E08-4402-8BCC-07CF64AD47EDQ34230034-77099774-FC49-49F9-B394-A42EA9ECFFADQ34286821-E9005B0A-B889-466D-9075-01F224F0ABEFQ34470713-99F933D2-BE4A-45DA-BCA9-6F4B0434855EQ34694926-2931EB7B-E56A-4CE6-9419-63ABC31A9FF2Q34737427-BC9BCF69-6AC2-4034-9950-4FC84FC0CD77Q34939045-10D55BC0-FB1B-4FC4-8028-78C930758942Q35005549-F55B4082-9DFF-4124-BF47-F04004F65181Q35118472-BB15E0A3-44A3-4C51-B5B4-39385A825E79Q35121985-6C61ACD6-684A-4B4B-965F-425011AC862AQ35276965-85238227-1EF3-4AE3-9CDF-D99DF0C7FB31Q35280233-C9915159-B8F0-4F4E-8153-4ECABC449105Q35285000-8E43C6DB-9DDE-468A-AFD5-F5F573C70C1CQ35307059-7BE7A7E7-D6A9-4B2E-9B5D-1FA8965EDF20Q35309352-EE99AC79-E9BA-47E4-BCEA-2139B124AD4BQ35328150-4AA69F0F-D0EF-4499-AA15-520D6F7E968DQ35332478-DE3DD162-3B81-4139-BDD6-6D146E07CB07Q35355587-28EC334D-5898-4AAF-8EEE-BF7BD4CC621BQ35539120-728518FE-2576-40ED-8BCE-93FCA23D8293Q35540772-76E142C0-012A-4832-BC5D-03425448CCAFQ35541055-68F673B3-AE60-4FE0-969F-733A88D5F603Q35541070-D1CAB5FC-85DB-4901-A6E7-C37FE7DF8E5BQ35543452-4CE222CA-3759-4073-854A-4EF319EE82E8Q35566190-AD1D84CC-9F6B-4DA8-8E79-1A5B9EFCE901Q35685332-0417754C-F60D-4F60-B746-E671EAF34D58Q35845962-7049BF83-BB86-4BF8-B872-E0C81FD80ACFQ35912731-4CEA1DBC-CA8A-40A3-8EA6-EC1F349E045CQ35952375-C89601F1-388A-4CA9-98E9-3DF5224DCCDFQ36343547-BEEEE92E-6D32-4DA0-875B-3982CC19E1F0Q36473436-1DEAAE0A-230E-4787-823A-54B667C3B9C7Q36482900-D922CA11-1057-4A86-8CDB-C16D049C0D9CQ36505466-FC2403D7-70E4-4E9A-A9F5-43FA02F2F3ABQ36632851-38594E82-9FC9-4F96-AA39-D630EF4037BCQ36636341-A9FC8F94-BDD1-4760-BD3E-D118480F5153Q36751113-5CAD05E1-32C8-40FB-9D80-8708E5302E46
P2860
In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic.
description
1986 nî lūn-bûn
@nan
1986年の論文
@ja
1986年学术文章
@wuu
1986年学术文章
@zh-cn
1986年学术文章
@zh-hans
1986年学术文章
@zh-my
1986年学术文章
@zh-sg
1986年學術文章
@yue
1986年學術文章
@zh
1986年學術文章
@zh-hant
name
In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic.
@en
In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic.
@nl
type
label
In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic.
@en
In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic.
@nl
prefLabel
In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic.
@en
In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic.
@nl
P2093
P2860
P356
P1476
In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic.
@en
P2093
Eliopoulos GM
Moellering RC Jr
Reiszner E
Spitzer PG
P2860
P304
P356
10.1128/AAC.30.4.532
P407
P577
1986-10-01T00:00:00Z